Vertex Pharmaceuticals Incorporated (VRTX) Stake Increased by Westpac Banking Corp
Westpac Banking Corp lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 52.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 116,152 shares of the pharmaceutical company’s stock after buying an additional 40,100 shares during the period. Westpac Banking Corp’s holdings in Vertex Pharmaceuticals were worth $17,407,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of VRTX. Jennison Associates LLC boosted its position in shares of Vertex Pharmaceuticals by 19.0% in the third quarter. Jennison Associates LLC now owns 6,017,766 shares of the pharmaceutical company’s stock worth $914,941,000 after buying an additional 962,644 shares during the period. Point72 Asset Management L.P. boosted its position in shares of Vertex Pharmaceuticals by 8,061.1% in the third quarter. Point72 Asset Management L.P. now owns 909,230 shares of the pharmaceutical company’s stock worth $138,239,000 after buying an additional 898,089 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Vertex Pharmaceuticals by 9,422.3% in the third quarter. Assenagon Asset Management S.A. now owns 893,380 shares of the pharmaceutical company’s stock worth $135,829,000 after buying an additional 883,998 shares during the period. Vanguard Group Inc. boosted its position in shares of Vertex Pharmaceuticals by 3.1% in the second quarter. Vanguard Group Inc. now owns 16,979,872 shares of the pharmaceutical company’s stock worth $2,188,196,000 after buying an additional 504,982 shares during the period. Finally, Fred Alger Management Inc. boosted its position in shares of Vertex Pharmaceuticals by 34.3% in the second quarter. Fred Alger Management Inc. now owns 1,624,480 shares of the pharmaceutical company’s stock worth $209,347,000 after buying an additional 414,501 shares during the period. 93.19% of the stock is owned by institutional investors and hedge funds.
Several analysts have recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $195.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, October 27th. BMO Capital Markets reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, September 27th. DA Davidson assumed coverage on Vertex Pharmaceuticals in a report on Friday, September 29th. They set a “buy” rating and a $200.00 price objective for the company. BTIG Research assumed coverage on Vertex Pharmaceuticals in a report on Friday, September 29th. They set a “buy” rating and a $200.00 price objective for the company. Finally, Oppenheimer increased their price objective on Vertex Pharmaceuticals from $175.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, January 4th. One research analyst has rated the stock with a sell rating, three have given a hold rating, twenty-five have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $175.89.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at $155.45 on Thursday. Vertex Pharmaceuticals Incorporated has a 1-year low of $80.06 and a 1-year high of $167.85. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $39,310.00, a PE ratio of 199.29, a price-to-earnings-growth ratio of 1.84 and a beta of 1.58.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The company had revenue of $578.20 million for the quarter, compared to analyst estimates of $522.07 million. During the same period last year, the company earned $0.16 earnings per share. The business’s revenue was up 39.7% compared to the same quarter last year. equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current year.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.